Boland Pens Op-Ed in Boston Globe on How Corporate Boards Can Curtail Sexual Harassment
21 November 2017
Partner Beth Boland wrote an op-ed that was published in the Boston Globe, “How Corporate Boards Can Curtail Sexual Harassment.”
In the piece, Boland, who is president of the New England Chapter of the National Association of Corporate Directors, offers corporate board members steps they can take to curtail sexual harassment including asking tough questions of management to gauge efforts in creating a culture of inclusion; reviewing corporate sexual harassment policies and investigation procedures; and prioritizing women and candidates of color for open board seats.
In the piece, Boland, who is president of the New England Chapter of the National Association of Corporate Directors, offers corporate board members steps they can take to curtail sexual harassment including asking tough questions of management to gauge efforts in creating a culture of inclusion; reviewing corporate sexual harassment policies and investigation procedures; and prioritizing women and candidates of color for open board seats.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”